Strategic partnerships Mainz Biomed has a history of collaborations and an integration with DoctorBox, plus a past partnership with CARE Diagnostica. Target potential distributor and healthcare IT partners to expand access to ColoAlert and related diagnostics in hospital networks, clinics, and digital health platforms.

Clinical validation The company positions itself around early cancer detection with clinical posters and participation in industry conferences. Leverage opportunities to present joint clinical studies, co-branding, and payer-relevant evidence with research partners to accelerate adoption and reimbursement talks.

Executive movement Appointment of a new Chairman of the Board in 2026 signals strategic shifts and governance updates. Engage C-level and board-aligned outreach to align on growth plans, capital strategy, and potential strategic investments or partnerships.

Market visibility Active participation in MEDICA, Digestive Disease Week, and other major conferences indicates a push for brand and product awareness. Develop event-focused outreach, lead capture, and post-event follow-ups with healthcare providers, KOLs, and diagnostic distributors.

Growth potential Revenue is currently modest with ongoing funding and multiple collaborations. Position value propositions around scalable, easy-to-use diagnostics, integration-ready platforms, and cost-effective screening solutions to attract distributors, CCs, and health systems seeking innovative cancer screening tools.